Hilal KIZILTUNÇ ÖZMEN
(Atatürk Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Erzurum, Türkiye)
Orhan SEZEN
(Atatürk Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Erzurum, Türkiye)
Meryem AKTAN
(Necmettin Erbakan Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Konya, Türkiye)
Burak ERDEMCİ
(Atatürk Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Erzurum, Türkiye)
Burcu SAĞLAM ALAN
(Antalya Eğitim ve Araştırma Hastanesi, Radyasyon Onkolojisi Anabilim Dalı, Antalya, Türkiye)
Mustafa Vecdi ERTEKİN
(Nişantaşı Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Bölümü, İstanbul, Türkiye)
Sinan EZİRMİK
(Nişantaşı Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Bölümü, İstanbul, Türkiye)
Yıl: 2020Cilt: 52Sayı: 1ISSN: 1308-8734 / 1308-8742Sayfa Aralığı: 73 - 76İngilizce

17 0
Comparision of Radiochemotherapy Applications that Committing with Two Different Chemotherapies Route in Locally Advanced Lung Cancer
Objective: This study investigated pre- and post-treatment tumor and lymph node dimension response rates and differences between side-effect profiles in patients with locally advanced inoperable nonsmall-cell lung cancer (NSCLC) receiving radiotherapy (RT) and concurrent chemotherapy (CT). Materials and Methods: A total of 30 inoperable patients who had not previously received RT and having a mean age of 58.73±8.65 years with sufficient hematological reserves and normal hepatic and renal functions were included in the study. Those with pleural effusion, supraventricular lymph node metastasis, and N3 lymph node involvement were excluded. Group I (n=15) received a 21-day 75 mg/m2 cisplatin (D1) and 15 mg/m2 vinorelbine (D1, D8), whereas Group II (n=15) received 45 mg/m2 paclitaxel and AUC2 carboplatin weekly. RT was administered using a linear accelerator device with the 3D conformal RT technique at 6-18 MV energy with a 1.8-2 Gy fraction for 6-7 weeks. Results: Patients were randomized into Group I receiving RT and concurrent cisplatin–vinorelbine and Group II receiving weekly paclitaxel–carboplatin CT. Pre- and post-treatment tumor and lymph node dimensions significantly differed in both groups (p<0.001 and p<0.01, respectively). No significant change was observed in post-RT tumor and lymph node dimensions in terms of applied CT regimens (p>0.05). Conclusion: The significant response achieved with concurrent RT and CT in groups I and II in the local advanced stage of NSCLC is important for local tumor control. Responses to treatment in the group of two arms did not differ.
DergiAraştırma MakalesiErişime Açık
  • 1. Detterbeck FC. Diagnosis and treatment of lung cancer, in An Evidence-Based Guide for the Practicing Physician. Phyledelphia, PA, WB Sounders, 2000. 2. Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102-10.
  • 3. Govindan R. Management of patients with non-small cell lung cancer and poor performance status. Curr Treat Options Oncol 2003; 4: 55-9. [CrossRef]
  • 4. Johnson DH, Turissi AT. Combined modality treatment for locally advanced, unresectable non-small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, editors. Lung Cancer: Principles and Practice. 2nd ed. Philadelphia: Lippincott Williams and Wilkins 2000: 910- 20.
  • 5. Rosen RJ. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065. Ann Intern Med 2019; 170: 740. [CrossRef]
  • 6. Parkin DM, Bray F, Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74- 108. [CrossRef]
  • 7. Ramaswamy AT, Toll BA, Chagpar AB, Judson BL. Smoking, cessation, and cessation counseling in patients with cancer: A population-based analysis. Cancer 2016; 122:1247-53. [CrossRef]
  • 8. Ginsberg RS, Vokes EE, Raben A. Non-small cell lung cancer. In: DeVita VT Sr, Hellman S, Rosenberg SA; eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott Raven; 1997; 858-911.
  • 9. Hu W, Fang J, Nie J, et al. Efficacy and safety of extended use of platinum-based doublet che motherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine (Baltimore) 2016; 95: e4183. [CrossRef]
  • 10. Artal Cortes A, Calera Urguizu L, Hernando Cubero J. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res 2015; 4: 191-7.
  • 11. Grili R, Oxman AD, Julian JA. Chemotherapy for advanced Non-small Cell Lung Cancer: How much benefit is Enough? J Clin Oncol 1993; 11: 1866-72. [CrossRef]
  • 12. Le Chevalier, R Arriagada, P Baldeyrou, et al. Inoperable Lung Epidermoid Cancer Non Metastasizing. A Phase II Trial Using Radiotherapy and Combined Chemotherapy. Bull Cancer 1985; 72: 25-9.
  • 13. Klastersky J. VP-16 and cisplatin in the treatment of non small cell lung cancer. Semin Oncol 1985; 12: 17-20.
  • 14. Depierre A, Chastang C, Quoix E, et al. Vinorelbine Versus Vinorelbine Plus Cisplatin in Advanced Non-Small Cell Lung Cancer: A Randomized Trial. Ann Oncol 1994; 5: 37-42. [CrossRef]
  • 15. Gralla RJ, Kardinal CG, Otten MC, et al. Vinorelbine in combination with cisplatin or mitomycin enhancing safety, efficacy and dose intensity. Lung Cancer 1994; 11: 119. [CrossRef]
  • 16. Gerber DE, Swanson P, Lopez-Chavez A, et al. Phase II study of olaratumab with paclitaxel/ carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer 2017; 111: 108-15. [CrossRef]
  • 17. Soejima K, Naoki K, İshioka K, et al. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2015; 75: 513-9. [CrossRef]
  • 18. Rosell R, Gonzales JL, Alberola V, et al. Single agent Paclitaxel by 3-hour infusion in the treatment of NSCLC: Links Between p53 and K-ras Gene Status and chemosensitivity. Semin Oncol 1995; 22: 12-18.
  • 19. Belani CP. Paclitaxel and Docetaxel combinations in NSCLC. Chest 2000; 117: 144-51. [CrossRef]
  • 20. Saad AS, Ghali RR, Shawki MA. A prospective randomized controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer. J Cancer Res Ther 2017; 13: 198-203. [CrossRef]
  • 21. Bonomi P, Kim K, Chang A, Jhonson D. Phase III trial comparing etoposide cisplatin versus Taxol with cisplatin G-CSF versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 1996; 15: 382.
  • 22. Morgan KM, Fischer BS, lee FY, et al. Gamma secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma. Mol Cancer Ther 2017; 16: 2759-69. [CrossRef]
  • 23. van der Burg ME, Vergote I, Onstenk W, et al. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and welltolerated treatment in patients with platinumresistant ovarian cancer. Eur J Cancer 2013; 49: 1254-63. [CrossRef]
  • 24. Scagliotti GV, Crino L, Pozzi E, et al. Phase I/II dose finding study of Paclitaxel and Carboplatin in advanced NSCLC. Lung Cancer 1999; 25: 39- 46. [CrossRef]
  • 25. Han BH, Xiu QY, Wang HM, et al. A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced nonsmall cell lung cancer (NSCLC). Chin J Oncol 2011; 33: 854-9.
  • 26. Belani CP, Kearns CM, Zuhowsky EG, et al. Phase I trial, including phatmacokinetic and pharmacodynamic correlations, of combination Paclitaxel and Carboplatin in patients with metastatic NSCLC. J Clin Oncol 1999; 17: 676-84. [CrossRef]
  • 27. Zhao J, Zhang X, Hu K, et al. Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel Administrated Every Three Weeks in Inoperable Advanced Non-small Cell Lung Cancer: A Retrospective Study from A Single Center. Chin J Lung Cancer 2016; 19: 731-7.
  • 28. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: hight-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66. [CrossRef]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.